Positron-Emission-Tomography in Diffuse Low-Grade Gliomas

Abstract The management of low-grade gliomas represents a challenge to the physician as a significant proportion may undergo malignant degeneration to a high-grade tumor. We present the positron emission tomography (PET) scans, using [18F] fluorodeoxyglucose (FDG), of 12 patients who have histological and/or clinical evidence of malignant degeneration of a low-grade glioma. Each scan displays a focal area of hypermetabolism similar to that of malignant gliomas which arise de novo. Three patients also underwent PET scanning prior to malignant degeneration. When the initial scan is compared with the postmalignant degeneration study, a difference in tumoral glucose uptake can be recognized. A region previously shown to be hypometabolic develops focal hypermetabolism as malignant changes evolve. This study displays the utility of FDG-PET in the evaluation of malignant degeneration of low-grade gliomas. The knowledge that a neoplasm has altered its biological behavior may influence subsequent therapeutic options. If these findings can be confirmed in larger series and by other investigators, it is possible that FDG-PET may be adopted as one of the diagnostic tools for guiding the management of low-grade gliomas.

Download Full-text

The integration of metabolic imaging in stereotactic procedures including radiosurgery: a review

Journal of Neurosurgery ◽

10.3171/jns.2002.97.supplement_5.0542 ◽

2002 ◽

Vol 97 ◽

pp. 542-550 ◽

Cited By ~ 35

Author(s):

Marc Levivier ◽

David Wikler ◽

Nicolas Massager ◽

Philippe David ◽

Daniel Devriendt ◽

...

Keyword(s):

Positron Emission Tomography ◽

Brain Tumors ◽

Treatment Planning ◽

Target Volume ◽

Emission Tomography ◽

Low Grade ◽

Content Type ◽

Positron Emission ◽

Pet Scanning ◽

Fine Print

Object. The authors review their experience with the clinical development and routine use of positron emission tomography (PET) during stereotactic procedures, including the use of PET-guided gamma knife radiosurgery (GKS). Methods. Techniques have been developed for the routine use of stereotactic PET, and accumulated experience using PET-guided stereotactic procedures over the past 10 years includes more than 150 stereotactic biopsies, 43 neuronavigation procedures, and 34 cases treated with GKS. Positron emission tomography—guided GKS was performed in 24 patients with primary brain tumors (four pilocytic astrocytomas, five low-grade astrocytomas or oligodendrogliomas, seven anaplastic astrocytomas or ependymomas, five glioblastomas, and three neurocytomas), five patients with metastases (single or multiple lesions), and five patients with pituitary adenomas. Conclusions. Data obtained with PET scanning can be integrated with GKS treatment planning, enabling access to metabolic information with high spatial accuracy. Positron emission tomography data can be successfully combined with magnetic resonance imaging data to provide specific information for defining the target volume for the radiosurgical treatment in patients with recurrent brain tumors, such as glioma, metastasis, and pituitary adenoma. This approach is particularly useful for optimizing target selection for infiltrating or ill-defined brain lesions. The use of PET scanning contributed data in 31 cases (93%) and information that was specifically utilized to adapt the target volume in 25 cases (74%). It would seem that the integration of PET data into GKS treatment planning may represent an important step toward further developments in radiosurgery: this approach provides additional information that may open new perspectives for the optimization of the treatment of brain tumors.

Download Full-text

Performance of dedicated breast positron emission tomography in the detection of small and low-grade breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-020-06088-1 ◽

2021 ◽

Author(s):

Satoshi Sueoka ◽

Shinsuke Sasada ◽

Norio Masumoto ◽

Akiko Emi ◽

Takayuki Kadoya ◽

...

Keyword(s):

Breast Cancer ◽

Positron Emission Tomography ◽

Emission Tomography ◽

Low Grade ◽

Positron Emission

Download Full-text

JAZF1–SUZ12 endometrial stromal sarcoma forming subserosal masses with extraordinary uptake of fluorodeoxyglucose on positron emission tomography: a case report

Diagnostic Pathology ◽

10.1186/s13000-019-0897-y ◽

2019 ◽

Vol 14 (1) ◽

Author(s):

Koto Fujiishi ◽

Shigenori Nagata ◽

Rieko Kano ◽

Chiaki Kubo ◽

Maasa Shirayanagi ◽

...

Keyword(s):

Positron Emission Tomography ◽

Endometrial Stromal Sarcoma ◽

Emission Tomography ◽

Low Grade ◽

Neoplastic Cells ◽

Pelvic Magnetic Resonance Imaging ◽

Stromal Sarcoma ◽

Positron Emission ◽

Mesenchymal Neoplasm ◽

The Right

Abstract Background Low-grade endometrial stromal sarcoma (ESS) is rare mesenchymal neoplasm, recently specified as harboring JAZF1–SUZ12 rearrangement. Typical JAZF1–SUZ12 ESS is slow growing, in which high uptake of fluorodeoxyglucose (FDG) on positron emission tomography (PET) and subserosal masses are quite unusual. Case presentation A 69-year-old Japanese woman complained of urinary incontinence. Pelvic magnetic resonance imaging showed uterine lesions composed of (1) a 9 × 8 × 7-cm mass protruding from the right-anterior wall, (2) a 4.5-cm mass attached to the right-posterior wall, and (3) a 6.5-cm intramural mass in the fundus. FDG-PET demonstrated maximum standardized uptake value of 13.28 confined to the two subserosal masses (1 & 2) in contrast to no uptake of the intramural mass (3). She was diagnosed with a high-grade uterine sarcoma concomitant with leiomyomas and underwent total hysterectomy with bilateral salpingo-oophorectomy and pelvic lymphadenectomy. The removed uterus had three tumors—two in the right-anterior and right-posterior subserosa, respectively, and the remaining in the fundal myometrium. Microscopically, the three tumors shared morphologic features characterized by neoplastic cells similar to proliferative-phase endometrial stromal cells, in which neither round-cell component, pleomorphism, nor high mitotic activity was recognized. Nuclear cyclin D1 immunostaining was identified 50% of neoplastic cells in the two subserosal tumors (1 &2) whereas < 1% positive cells in the intramural component (3). Reverse transcriptase-polymerase chain reaction showed the same-sized electrophoretic bands indicating JAZF1–SUZ12 gene fusion shared by the three uterine tumors and a focal tumor extension into the extrauterine vein. The patient is alive without evidence of recurrence at 14 months after surgery. Conclusions Pathologists and clinicians should not exclude the possibility of JAZF1–SUZ12 ESS even when uterine subserosal masses demonstrate extraordinary FDG uptake on PET. Molecular analysis is helpful for diagnostic confirmation of JAZF1–SUZ12 ESS with a complex growth pattern.

Download Full-text

Positron Emission Tomography (PET) for Staging Low-Grade Non-Hodgkin's Lymphomas (NHL)

Cancer Biotherapy & Radiopharmaceuticals ◽

10.1089/108497801753131372 ◽

2001 ◽

Vol 16 (4) ◽

pp. 297-304 ◽

Cited By ~ 50

Author(s):

F. Najjar ◽

R. Hustinx ◽

G. Jerusalem ◽

G. Fillet ◽

P. Rigo

Keyword(s):

Positron Emission Tomography ◽

Emission Tomography ◽

Low Grade ◽

Positron Emission ◽

Hodgkin's Lymphomas

Download Full-text

[11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas

ISRN Oncology ◽

10.1155/2014/463152 ◽

2014 ◽

Vol 2014 ◽

pp. 1-6 ◽

Cited By ~ 3

Author(s):

Matteo Santoni ◽

Cristina Nanni ◽

Alessandro Bittoni ◽

Gabriele Polonara ◽

Alessandro Paccapelo ◽

...

Keyword(s):

Positron Emission Tomography ◽

Residual Disease ◽

Karnofsky Performance Status ◽

Performance Status ◽

High Sensitivity ◽

Emission Tomography ◽

Low Grade ◽

Postoperative Imaging ◽

Positron Emission ◽

Met Pet

We investigated the sensitivity and specificity of [11C]-methionine positron emission tomography ([11C]-MET PET) in the management of glioma patients. We retrospectively analysed data from 53 patients with primary gliomas (16 low grade astrocytomas, 15 anaplastic astrocytomas and 22 glioblastomas) and Karnofsky Performance Status (KPS) > 70. Patients underwent [11C]-MET PET scans (N=249) and parallel contrast-enhanced MRI (N=193) and/or CT (N=113) controls. In low grade glioma patients, MRI or CT findings associated with [11C]-MET PET additional data allowed discrimination residual disease from postsurgical changes in 96.22% of these cases. [11C]-MET PET early allowed detection of malignant progression from low grade to anaplastic astrocytoma with high sensitivity (91.56%) and specificity (95.18%). In anaplastic astrocytomas, we registered high sensitivity (93.97%) and specificity (95.18%) in the postoperative imaging and during the followup of these patients. In GBM patients, CT and/or MRI scans with additional [11C]-MET PET data registered a sensitivity of 96.92% in the postsurgical evaluation and in the tumour assessment during temozolomide therapy. A significant correlation was found between [11C]-MET mean uptake index and histologic grading (P<0.001). These findings support the notion that complementary information derived from [11C]-MET PET may be helpful in postoperative and successive tumor assessment of glioma patients.

Download Full-text